Concepedia

Diane Rensvold

DR

Statistics

Publications

7

Citations

341

H-Index

7

Active since

2009

Affiliations

Arizona Oncology(Current)

University of Arizona

Indiana University – Purdue University Indianapolis

Diane Rensvold is an author at Arizona Oncology specializing in pharmacology, medicine, and oncology.

Publications per year

2009–2012

7

Publications

7

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

Daruka Mahadevan, E. Gabriela Chiorean, Wayne B. Harris et al. · European Journal of Cancer · 2012 · 134 citations

Medicine, Oncology, Pharmacology +11

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors

Daruka Mahadevan, Ruth Plummer, Matthew Squires et al. · Annals of Oncology · 2011 · 88 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Phase I Trial of AEG35156 an Antisense Oligonucleotide to XIAP Plus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Daruka Mahadevan, Pavani Chalasani, Diane Rensvold et al. · American Journal of Clinical Oncology · 2012 · 44 citations

Medicine, Oncology, Pharmacology +17

Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors

E. Gabriela Chiorean, Daruka Mahadevan, Wayne B. Harris et al. · Journal of Clinical Oncology · 2009 · 26 citations

Medicine, Oncology, Pharmacology +17

First-in-human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors.

Daruka Mahadevan, Diane Rensvold, Sandra Kurtin et al. · Journal of Clinical Oncology · 2012 · 21 citations

Medicine, Oncology, Pharmacology +13

1–5 of 7